HBM HOLDINGS-B (02142) rose more than 5%, reaching HK$13.94 at press time with a turnover of HK$17.20 million. The company announced a strategic collaboration with Evinova during the 8th China International Import Expo (CIIE). Under the agreement, both parties will leverage AI and digital technologies to enhance the efficiency of innovative biotherapy development, jointly building an open ecosystem for AI-driven drug discovery.

Previously, at its Global R&D Day event in Shanghai, HBM HOLDINGS-B unveiled its Hu-mAtrIx™ AI platform, featuring the first fully human AIHCAb model—a heavy-chain antibody (HCAb) generation and screening system. This model integrates a fine-tuned large language model (LLM) for sequence generation, supported by high-precision AI classification and druggability prediction, utilizing proprietary HarbourMice® platform data. Unlike traditional screening methods, the platform establishes a closed-loop workflow combining AI design, intelligent screening, and wet-lab validation.